Halozyme Therapeutics, Inc. (HALO) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 210 PAGES: 40

More Info
									            Halozyme Therapeutics, Inc. (HALO) - Financial and Strategic SWOT
                                    Analysis Review
        Reference Code: GDPH44899FSA                                                                                          Publication Date: MAR 2013

          11388 Sorrento Valley Road                         Phone              +1 858 7948889                  Revenue          42.3 (million USD)
          San Diego, CA                                      Fax                +1 858 7048311                  Net Profit       -19.77 (million USD)
          92121                                              Website            www.halozyme.com                Employees        135
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange           HALO [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       Halozyme Therapeutics, Inc. (Halozyme) is a bio-pharmaceutical company. It develops and markets drug delivery products for
       oncology, dermatology and endocrinology markets. Its products portfolio depends on intellectual property covering the family of
       human enzymes known as hyaluronidases and additional enzymes affecting the extracellular matrix. The company’s Enhanze
       technology is a novel drug delivery platform proposed to enhance the absorption and dispersion of biologics. Its products include
       Cumulase for in vitro fertilization and Hylenex an agent for drug and fluid infusion. The company has partnerships with Pfizer,
       Roche, Baxter, Intrexon and ViroPharma.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Halozyme Therapeutics, Inc., SWOT Analysis
         Gregory I. Frost, Ph.D.             Chief Executive Officer                  Strengths                              Weaknesses
         Connie L. Matsui                    Director
                                                                                      Licensing Partnerships                 Dependence on Third Party
         John S. Patton, Ph.D.               Director                                                                        Contractors
                                                                                      Focused Research and
         Robert L. Engler                    Director
                                                                                      Development
         Kathryn E. Falberg                  Director
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Opportunities                          Threats

       Share Data                                                                     Rising Healthcare Expenditure Demographic Trends
         Halozyme Therapeutics, Inc.                                                  in the US
                                                                                                                    Increasing Competition
        Share Price (USD) as on 15-Mar-                                  5.54         Collaboration with Pfizer
        2013
        EPS (USD)                                                       -0.19
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        Market Cap (million USD)                                         624         GlobalData

        Enterprise Value (million USD)                                   537
        Shares Outstanding (million)                                     113
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Feb 25, 2013         Halozyme Therapeutics Reports Revenue Of
                                                                                                           $42.3m In 2012
                                                                                      Nov 08, 2012         Halozyme Therapeutics Reports Revenue Of
                                                                                                           $5.3m In Q3 2012
                                                                                      Aug 06, 2012         Halozyme Therapeutics Reports Revenue Of
                                                                                                           $7.8m For Q2 2012
                                                                                      May 07, 2012         Halozyme Reports Revenue Of $7.4m In Q1
                                                                                                           2012
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Halozyme Therapeutics, Inc. (HALO) - Financial and Strategic                                                                   Reference Code: GDPH44899FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Halozyme Therapeutics, Inc. - Key Facts ........................................................................................................................................... 5
       Halozyme Therapeutics, Inc. - Key Employees .................................................................................................................................. 6
       Halozyme Therapeutics, Inc. - Key Employee Biographies ................................................................................................................ 7
       Halozyme Therapeutics, Inc. - Major Products and Services ............................................................................................................. 8
       Halozyme Therapeutics, Inc. - Pharmaceutical Pipeline Products Data ............................................................................................. 9
          Halozyme Therapeutics, Inc., Pipeline Products by Therapy Area ................................................................................................. 9
          Halozyme Therapeutics, Inc., Pipeline Products by Development Phase ..................................................................................... 10
       Halozyme Therapeutics, Inc. - History .............................................................................................................................................. 12
       Halozyme Therapeutics, Inc. - Company Statement ........................................................................................................................ 15
       Halozyme Therapeutics, Inc. - Locations And Subsidiaries .............................................................................................................. 16
          Head Office ................................................................................................................................................................................... 16
       Section 2 – Company Analysis ......................................................................................................................................................... 17
       Halozyme Therapeutics, Inc. - Business Description ....................................................................................................................... 17
       Halozyme Therapeutics, Inc. - Corporate Strategy........................................................................................................................... 18
       Halozyme Therapeutics, Inc. - SWOT Analysis ................................................................................................................................ 19
          SWOT Analysis - Overview........................................................................................................................................................... 19
          Halozyme Therapeutics, Inc. - Strengths ...................................................................................................................................... 19
             Strength - Licensing Partnerships ............................................................................................................................................. 19
             Strength - Focused Research and Development ...................................................................................................................... 19
             Strength - Proprietary Enhanze Technology ............................................................................................................................. 19
          Halozyme Therapeutics, Inc. - Weaknesses ................................................................................................................................. 20
             Weakness - Dependence on Third Party Contractors ............................................................................................................... 20
          Halozyme Therapeutics, Inc. - Opportunities ................................................................................................................................ 20
             Opportunity - Rising Healthcare Expenditure in the US............................................................................................................. 20
             Opportunity - Collaboration with Pfizer ...................................................................................................................................... 20
          Halozyme Therapeutics, Inc. - Threats ......................................................................................................................................... 20
             Threat - Demographic Trends ................................................................................................................................................... 20
             Threat - Increasing Competition ................................................................................................................................................ 21
             Threat - Stringent Regulations .................................................................................................................................................. 21
             Threat - Increased Pricing Control............................................................................................................................................. 21
       Halozyme Therapeutics, Inc. - Key Competitors .............................................................................................................................. 22
       Section 3 – Company Financial Ratios ............................................................................................................................................. 23
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 23
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 23
       Performance Chart ........................................................................................................................................................................... 25
       Financial Performance...................................................................................................................................................................... 25
       Financial Ratios - Interim Ratios....................................................................................................................................................... 26
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 27
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 28
          Halozyme Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013............................................... 28
          Halozyme Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 .............................................. 29


Halozyme Therapeutics, Inc. (HALO) - Financial and Strategic                                                                                                   Reference Code: GDPH44899FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Halozyme Therapeutics, Inc., Recent Deals Summary .................................................................................................................... 30
       Section 5 – Company’s Recent Developments ................................................................................................................................ 31
          Halozyme Therapeutics, Inc., Recent Developments ................................................................................................................... 31
             Feb 25, 2013: Halozyme Therapeutics Reports Revenue Of $42.3m In 2012 .......................................................................... 31
             Nov 08, 2012: Halozyme Therapeutics Reports Revenue Of $5.3m In Q3 2012 ...................................................................... 32
             Aug 06, 2012: Halozyme Therapeutics Reports Revenue Of $7.8m For Q2 2012 .................................................................... 33
             May 07, 2012: Halozyme Reports Revenue Of $7.4m In Q1 2012 ........................................................................................... 33
             Mar 09, 2012: Halozyme Therapeutics Reports Revenue Of $2.4m In Q4 2011 ...................................................................... 34
       Section 6 – Appendix ....................................................................................................................................................................... 36
          Methodology ................................................................................................................................................................................. 36
          Ratio Definitions ............................................................................................................................................................................ 36
          About GlobalData ...........................................................................................................................
								
To top